- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- ID number:
- 6403
Provisional Schedule
- Committee meeting:
- 02 December 2025
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- GlaxoSmithKline (niraparib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Ovacome
- Ovarian Cancer Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- AstraZeneca
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 May 2025 | Invitation to participate |
| 14 March 2025 - 11 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we select topics for development, please see our page about prioritising our guidance topics